非小细胞肺癌组织中ERCC1和RRM1表达与抗肿瘤治疗的疗效及预后关系

李竟长; 倪秉强; 陈日新; 朱州

doi:10.7619/jcmp.201301006

非小细胞肺癌组织中ERCC1和RRM1表达与抗肿瘤治疗的疗效及预后关系

广西壮族自治区柳州市人民医院肿瘤科,广西柳州,545006

基金项目: 中国高校医学期刊临床专项资金

详细信息

中图分类号: R734.2
计量
- 文章访问数: 317
- HTML全文浏览量: 31
- PDF下载量: 13
出版历程
- 发布日期: 2013-05-01

Expression of excision repair cross complementing gene1 and ribonucleotide reductase M1 in non-small cell lung cancer tissue and therapeutic effects of trecombinant human endostatin combined with gemcitabine/cisplatin and its prognostic relationship

摘要

摘要: 目的探讨核苷酸还原酶亚单位M1 (RRM1)和核苷酸切除修复交叉互补基因1(ERCC1)蛋白在ⅢB和Ⅳ期非小细胞肺癌(NSCLC)中的表达,及其对重组人血管内皮抑制素(恩度)联合吉西他滨/奈达铂化疗疗效的预测.方法采用免疫组织化学方法检测51例ⅢB～Ⅳ期肺癌患者组织中ERCC1和RRM1的表达水平.经过4周期以上恩度联合吉西他滨/奈达铂方案化疗,分析比较不同ERCC1和RRM1表达水平与NSCLC治疗预后的关系.结果 NSCLC组织中ERCC1的阳性率为43.1％,RRM1的阳性率为62.7％.RRM1与ERCC1蛋白表达显著正相关.RRM1和ERCC1表达均为阴性组的有效率为72.2％；二者表达均为阳性组为19.0％；二者表达任一阳性组为58.3％,3组之间比较差异均有统计学意义；ERCC1和RRM1低表达的患者生存期明显长于高表达者.结论 ERCC1和RRM1的表达可作为NSCLC患者恩度联合吉西他滨/奈达铂方案化疗敏感性及其预后判断的指标之一.
- 非小细胞肺癌 /
- 核苷酸切除修复交错互补基因-1 /
- 核糖核苷酸还原酶亚单位M1 /
- 免疫组织化学 /
- 吉西他滨 /
- 奈达铂

HTML全文

参考文献(10)

Olaussen K A, Dunant A, Fouret P. DNA repair by ERCC1 in non small cell lung cancer and cisplatin-based adjuvant chemotherapy [J]. N Earl J Med, 2006, (10):983.

Martin L P, Hamilton T C, Schilder R J. Platinum resistance:the role of DNA repair pathways [J]. Clinical Cancer Research, 2008(5):1291.

程刚. 非小细胞肺癌"个体化"化疗研究进展 [J]. 中国肺癌杂志, 2008(1):10.

Seetharam R N, Sood A, Basu-mallick A. Oxaliplatin No sistance induced by ERCC1 up-regulation is abrogated by siRNA mediated gene silencing in human colorectal cancer cells [J]. Anticancer Research, 2010(7):2531.

Kirschner K, Melton D W. Multiple roles of the ERCC1XPF endonuclease in DNA repair and resistance to anticancer drags [J]. Anticancer Research, 2010(9):3223.

Kim S O, Jeong J Y, Kim M R. Efficacy of gmeitabine in ptients with non-small cell lung cancer according to promoter polymorphisms of the ribonueleotide reducume Mi gene [J]. Clinical Cancer Research, 2008, (10):3083.

Croteau D L, Peng Y, Van Houten B. DNA repair gets physical:mapping an XPA-binding site on ERCC1 [J]. DNA Repair (Amat), 2008(5):819.

Pan J, Lin J, Izzo J G. Genetic susceptibility to esophageal cancer:the role of the nueleotide excision repair pathway [J]. Carcinogenesis, 2009(5):785.

Reynolds C, Obasaju C, Schell M J. Randomized phase Ⅲ trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in Non small cell lung cancer [J]. Journal of Clinical Oncology, 2009, (34):5808.

Itssaka S, Komaki R, Herbst R S. Endostatin improves radioresponse and blocks tumor revascuhrization after radiation therapy for A431 xenografis in mice [J]. International Journal of Radiation Oncology, Biology, Physics, 2007(3):870.

施引文献

资源附件(0)

计量

文章访问数: 317
HTML全文浏览量: 31
PDF下载量: 13
被引次数: 0

非小细胞肺癌组织中ERCC1和RRM1表达与抗肿瘤治疗的疗效及预后关系

计量

出版历程

Expression of excision repair cross complementing gene1 and ribonucleotide reductase M1 in non-small cell lung cancer tissue and therapeutic effects of trecombinant human endostatin combined with gemcitabine/cisplatin and its prognostic relationship

计量

出版历程

目录